Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer
(1) Background: Somatic and germline alterations can be commonly found in prostate cancer (PCa) patients. The aim of our present study was to perform a comprehensive review of the current literature in order to examine the impact of BRCA mutations in the context of PCa as well as their significance...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/3/86 |
| _version_ | 1797241518877048832 |
|---|---|
| author | Nikolaos Kalampokis Christos Zabaftis Theodoros Spinos Markos Karavitakis Ioannis Leotsakos Ioannis Katafigiotis Henk van der Poel Nikolaos Grivas Dionysios Mitropoulos |
| author_facet | Nikolaos Kalampokis Christos Zabaftis Theodoros Spinos Markos Karavitakis Ioannis Leotsakos Ioannis Katafigiotis Henk van der Poel Nikolaos Grivas Dionysios Mitropoulos |
| author_sort | Nikolaos Kalampokis |
| collection | DOAJ |
| description | (1) Background: Somatic and germline alterations can be commonly found in prostate cancer (PCa) patients. The aim of our present study was to perform a comprehensive review of the current literature in order to examine the impact of BRCA mutations in the context of PCa as well as their significance as genetic biomarkers. (2) Methods: A narrative review of all the available literature was performed. Only “landmark” publications were included. (3) Results: Overall, the number of PCa patients who harbor a BRCA2 mutation range between 1.2% and 3.2%. However, BRCA2 and BRCA1 mutations are responsible for most cases of hereditary PCa, increasing the risk by 3–8.6 times and up to 4 times, respectively. These mutations are correlated with aggressive disease and poor prognosis. Gene testing should be offered to patients with metastatic PCa, those with 2–3 first-degree relatives with PCa, or those aged < 55 and with one close relative with breast (age ≤ 50 years) or invasive ovarian cancer. (4) Conclusions: The individualized assessment of BRCA mutations is an important tool for the risk stratification of PCa patients. It is also a population screening tool which can guide our risk assessment strategies and achieve better results for our patients and their families. |
| first_indexed | 2024-04-24T18:24:36Z |
| format | Article |
| id | doaj.art-6f7cc4fd9ae7442ea94424888ba810a1 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-04-24T18:24:36Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-6f7cc4fd9ae7442ea94424888ba810a12024-03-27T13:32:40ZengMDPI AGCurrent Oncology1198-00521718-77292024-02-013131162116910.3390/curroncol31030086Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate CancerNikolaos Kalampokis0Christos Zabaftis1Theodoros Spinos2Markos Karavitakis3Ioannis Leotsakos4Ioannis Katafigiotis5Henk van der Poel6Nikolaos Grivas7Dionysios Mitropoulos8Department of Urology, G. Hatzikosta General Hospital, 45001 Ioannina, GreeceDepartment of Laparoscopy and Endourology, Central Urology, Lefkos Stavros the Athens Clinic, PC 11528 Athens, GreeceDepartment of Urology, University of Patras Hospital, 26504 Patras, GreeceDepartment of Laparoscopy and Endourology, Central Urology, Lefkos Stavros the Athens Clinic, PC 11528 Athens, GreeceDepartment of Laparoscopy and Endourology, Central Urology, Lefkos Stavros the Athens Clinic, PC 11528 Athens, GreeceDepartment of Laparoscopy and Endourology, Central Urology, Lefkos Stavros the Athens Clinic, PC 11528 Athens, GreeceDepartment of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The NetherlandsDepartment of Laparoscopy and Endourology, Central Urology, Lefkos Stavros the Athens Clinic, PC 11528 Athens, GreeceDepartment of Urology, Medical School, National & Kapodistrian University of Athens, 14122 Athens, Greece(1) Background: Somatic and germline alterations can be commonly found in prostate cancer (PCa) patients. The aim of our present study was to perform a comprehensive review of the current literature in order to examine the impact of BRCA mutations in the context of PCa as well as their significance as genetic biomarkers. (2) Methods: A narrative review of all the available literature was performed. Only “landmark” publications were included. (3) Results: Overall, the number of PCa patients who harbor a BRCA2 mutation range between 1.2% and 3.2%. However, BRCA2 and BRCA1 mutations are responsible for most cases of hereditary PCa, increasing the risk by 3–8.6 times and up to 4 times, respectively. These mutations are correlated with aggressive disease and poor prognosis. Gene testing should be offered to patients with metastatic PCa, those with 2–3 first-degree relatives with PCa, or those aged < 55 and with one close relative with breast (age ≤ 50 years) or invasive ovarian cancer. (4) Conclusions: The individualized assessment of BRCA mutations is an important tool for the risk stratification of PCa patients. It is also a population screening tool which can guide our risk assessment strategies and achieve better results for our patients and their families.https://www.mdpi.com/1718-7729/31/3/86prostate cancergenomic screeningmutations |
| spellingShingle | Nikolaos Kalampokis Christos Zabaftis Theodoros Spinos Markos Karavitakis Ioannis Leotsakos Ioannis Katafigiotis Henk van der Poel Nikolaos Grivas Dionysios Mitropoulos Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer Current Oncology prostate cancer genomic screening mutations |
| title | Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer |
| title_full | Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer |
| title_fullStr | Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer |
| title_full_unstemmed | Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer |
| title_short | Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer |
| title_sort | review on the role of brca mutations in genomic screening and risk stratification of prostate cancer |
| topic | prostate cancer genomic screening mutations |
| url | https://www.mdpi.com/1718-7729/31/3/86 |
| work_keys_str_mv | AT nikolaoskalampokis reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer AT christoszabaftis reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer AT theodorosspinos reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer AT markoskaravitakis reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer AT ioannisleotsakos reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer AT ioanniskatafigiotis reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer AT henkvanderpoel reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer AT nikolaosgrivas reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer AT dionysiosmitropoulos reviewontheroleofbrcamutationsingenomicscreeningandriskstratificationofprostatecancer |